UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia

Genes and Development

Volumn 30, Issue 5, 2016, Pages 508-521

  Benyoucef, Aissa ^a,b   Palii, Carmen G ^a,b   Wang, Chaochen ^c   Porter, Christopher J ^a   Chu, Alphonse ^a   Dai, Fengtao ^a   Tremblay, Véronique ^b   Rakopoulos, Patricia ^a   Singh, Kulwant ^a,b   Huang, Suming ^d   Pflumio, Francoise ^e,f,g   Hébert, Josée ^h,i   Couture, Jean Francois ^b   Perkins, Theodore J ^a,b   Ge, Kai ^c   Dilworth, F Jeffrey ^a,b   Brand, Marjorie ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e INSTITUT DE RADIOBIOLOGIE CELLULAIRE ET MOLÉCULAIRE   (France)

^f INSERM   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

ⁱ MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Epigenetics; Histone demethylase inhibitor; Histone demethylation; Leukemia; TAL1; UTX

Indexed keywords

HISTONE 3 DEMETHYLASE UTX; HISTONE H3; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HISTONE DEMETHYLASE; NUCLEAR PROTEIN; ONCOPROTEIN; TAL1 PROTEIN, HUMAN; UTX PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; HISTONE DEMETHYLATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HISTONE DEMETHYLASES; HUMANS; NUCLEAR PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS;

EID: 84959520560     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.276790.115     Document Type: Article

References (54)

1. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E, Salcini AE, Helin K. 2007. UTX andJMJD3 are histone H3K27 demethylases involved in HOXgene regulation and development. Nature 449: 731-734.
2. Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, CalvoJ, Fontenay M, Boissel N, Dombret H, Baruchel A, Landman-Parker J, et al. 2009. NOTCH is a key regulator of humanT-cell acute leukemia initiating cell activity. Blood 113:1730-1740.
3. Brand M, Rampalli S, Chaturvedi CP, Dilworth FJ. 2008. Analysisof epigenetic modifications of chromatin at specific gene lociby native chromatin immunoprecipitation of nucleosomesisolated using hydroxyapatite chromatography. Nat Protoc3: 398-409.
4. Chaturvedi CP, Somasundaram B, Singh K, Carpenedo RL, Stanford WL, Dilworth FJ, Brand M. 2012. Maintenance of gene silencingby the coordinate action of the H3K9methyltransferase G9a/KMT1C and the H3K4 demethylaseJarid1a/KDM5A. Proc Natl Acad Sci 109: 18845-18850.
5. Cho YW, Hong T, Hong S, Guo H, Yu H, Kim D, Guszczynski T, Dressler GR, Copeland TD, Kalkum M, et al. 2007. PTIP associateswith MLL3-and MLL4-containing histone H3 lysine 4methyltransferase complex. J Biol Chem 282: 20395-20406.
6. Condorelli GL, Facchiano F, Valtieri M, Proietti E, Vitelli L, Lulli V, Huebner K, Peschle C, Croce CM. 1996. T-cell-directedTAL-1 expression induces T-cell malignancies in transgenicmice. Cancer Res 56: 5113-5119.
7. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, et al. 2011.Selective killing of mixed lineage leukemia cells by a potentsmall-molecule DOT1L inhibitor. Cancer Cell 20: 53-65.
8. Dawson MA, Kouzarides T. 2012. Cancer epigenetics: frommechanism to therapy. Cell 150: 12-27.
9. De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, Gianfelici V, Geerdens E, Clappier E, Porcu M, et al. 2013.Exome sequencing identifies mutation in CNOT3 and ribosomalgenes RPL5 and RPL10 in T-cell acute lymphoblasticleukemia. Nat Genet 45: 186-190.
10. Demers C, Chaturvedi CP, Ranish JA, Juban G, Lai P, Morle F, Aebersold R, Dilworth FJ, Groudine M, Brand M. 2007. Activator-mediated recruitment of the MLL2 methyltransferasecomplex to the β-globin locus. Mol Cell 27: 573-584.
11. Deutsch EW, Mendoza L, Shteynberg D, Farrah T, Lam H, Tasman N, Sun Z, Nilsson E, Pratt B, Prazen B, et al. 2010. A guidedtour of the Trans-Proteomic Pipeline. Proteomics 10:1150-1159.
12. The ENCODE Project Consortium. 2012. An integrated encyclopediaof DNA elements in the human genome. Nature 489:57-74.
13. Ezponda T, Licht JD. 2014. Molecular pathways: deregulation ofhistone h3 lysine 27 methylation in cancer-different paths,same destination. Clin Cancer Res 20: 5001-5008.
14. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, RaimondiSC, Behm FG, Pui CH, Downing JR, Gilliland DG, et al. 2002. Gene expression signatures define novel oncogenicpathways inTcell acute lymphoblastic leukemia. Cancer Cell1: 75-87.
15. Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S, Soulier J, Boissel N, Leblanc T, Baruchel A, et al. 2011. Expressionof CD34 and CD7 on human T-cell acute lymphoblasticleukemia discriminates functionally heterogeneous cell populations.Leukemia 25: 1249-1258.
16. Hong S, Cho YW, Yu LR, Yu H, Veenstra TD, Ge K. 2007. Identificationof JmjC domain-containing UTX and JMJD3 as histoneH3 lysine 27 demethylases. Proc Natl Acad Sci 104:18439-18444.
17. Hu X, Ybarra R, Qiu Y, Bungert J, Huang S. 2009. Transcriptionalregulation by TAL1: a link between epigenetic modificationsand erythropoiesis. Epigenetics 4: 357-361.
18. Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, Mazo A, Eisenbach L, Canaani E. 2007. Knockdownof ALR (MLL2) reveals ALR target genes and leads to alterationsin cell adhesion and growth. Mol Cell Biol 27:1889-1903.
19. Kelliher MA, Seldin DC, Leder P. 1996. Tal-1 induces T cell acutelymphoblastic leukemia accelerated by casein kinase IIα.EMBO J 15: 5160-5166.
20. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL.2013. TopHat2: accurate alignment of transcriptomes in thepresence of insertions, deletions and gene fusions. GenomeBiol 14: R36.
21. Kim JH, Sharma A, Dhar SS, Lee SH, Gu B, Chan CH, Lin HK, Lee MG. 2014. UTX and MLL4 coordinately regulate transcriptionalprograms for cell proliferation and invasiveness inbreast cancer cells. Cancer Res 74: 1705-1717.
22. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. 2012. Aselective jumonji H3K27 demethylase inhibitor modulatesthe proinflammatory macrophage response. Nature 488:404-408.
23. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. 2014. Kruidenier,et al. reply. Nature 514: E2.
24. Kusy S, Gerby B, Goardon N, Gault N, Ferri F, Gérard D, Armstrong F, Ballerini P, Cayuela JM, Baruchel A, et al. 2010.NKX3.1 is a direct TAL1 target gene that mediates proliferationof TAL1-expressing human T cell acute lymphoblasticleukemia. J Exp Med 207: 2141-2156.
25. Lecuyer E, Hoang T. 2004. SCL: from the origin of hematopoiesisto stem cells and leukemia. Exp Hematol 32: 11-24.
26. Lee S, Lee JW, Lee SK. 2012. UTX, a histone H3-lysine 27 demethylase,acts as a critical switch to activate the cardiac developmentalprogram. Dev Cell 22: 25-37.
27. Liu H, Chiang MY, Pear WS. 2011. Critical roles of NOTCH1 inacute T-cell lymphoblastic leukemia. Int J Hematol 94:118-125.
28. Love MI, HuberW, Anders S. 2014. Moderated estimation of foldchange and dispersion for RNA-seq data with DESeq2. GenomeBiol 15: 550.
29. Miller SA, Mohn SE,Weinmann AS. 2010. Jmjd3 and UTX play ademethylase-independent role in chromatin remodeling toregulate T-box family member-dependent gene expression.Mol Cell 40: 594-605.
30. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. 2003. A statisticalmodel for identifying proteins by tandem mass spectrometry.Anal Chem 75: 4646-4658.
31. Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, BakogianniS, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, et al. 2014. Contrasting roles of histone 3 lysine 27 demethylasesin acute lymphoblastic leukaemia. Nature 514: 513-517.
32. Palii CG, Pasha R, Brand M. 2011a. Lentiviral-mediated knockdownduring ex vivo erythropoiesis of human hematopoieticstem cells. J Vis Exp doi: 10.3791/2813.
33. Palii CG, Perez-Iratxeta C, Yao Z, Cao Y, Dai F, Davison J, AtkinsH, Allan D, Dilworth FJ, Gentleman R, et al. 2011b. Differentialgenomic targeting of the transcription factor TAL1 in alternatehaematopoietic lineages. EMBO J 30: 494-509.
34. Palomero T, Ferrando A. 2009. Therapeutic targeting ofNOTCH1 signaling in T-cell acute lymphoblastic leukemia.Clin Lymphoma Myeloma 9: S205-S210.
35. Peirs S, Matthijssens F, Goossens S, Van deWalle I, Ruggero K, deBock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, et al.2014. ABT-199 mediated inhibition of BCL-2 as a novel therapeuticstrategy in T-cell acute lymphoblastic leukemia. Blood124: 3738-3747.
36. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, DaSilva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, et al. 2013. Direct reversal of glucocorticoid resistance byAKT inhibition in acute lymphoblastic leukemia. CancerCell 24: 766-776.
37. Pui CH, Robison LL, Look AT. 2008. Acute lymphoblastic leukaemia.Lancet 371: 1030-1043.
38. Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilitiesfor comparing genomic features. Bioinformatics 26: 841-842.
39. SandaT, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, MaW, Tatarek J, Ahn Y, Kelliher MA, et al. 2012. Coretranscriptional regulatory circuit controlled by the TAL1complex in human T cell acute lymphoblastic leukemia. CancerCell 22: 209-221.
40. Sen GL, Webster DE, Barragan DI, Chang HY, Khavari PA. 2008.Control of differentiation in a self-renewing mammalian tissueby the histone demethylase JMJD3. Genes Dev 22:1865-1870.
41. Shechter D, Dormann HL, Allis CD, Hake SB. 2007. Extraction,purification and analysis of histones. Nat Protoc 2:1445-1457.
42. Shilatifard A. 2012. The COMPASS family of histone H3K4methylases: mechanisms of regulation in development anddisease pathogenesis. Annu Rev Biochem 81: 65-95.
43. Shpargel KB, Sengoku T, Yokoyama S, Magnuson T. 2012. UTXand UTY demonstrate histone demethylase-independentfunction in mouse embryonic development. PLoS Genet 8:e1002964.
44. Simon C, Chagraoui J, Krosl J, Gendron P,Wilhelm B, Lemieux S, Boucher G, Chagnon P, Drouin S, Lambert R, et al. 2012.Akeyrole for EZH2 and associated genes in mouse and human adultT-cell acute leukemia. Genes Dev 26: 651-656.
45. Thieme S, Gyarfas T, Richter C, Ozhan G, Fu J, Alexopoulou D, Muders MH, Michalk I, Jakob C, Dahl A, et al. 2013. The histonedemethylase UTX regulates stem cell migration and hematopoiesis.Blood 121: 2462-2473.
46. Thoms JA, BirgerY, Foster S, Knezevic K, KirschenbaumY, ChandrakanthanV, Jonquieres G, Spensberger D, Wong JW, Oram SH, et al. 2011. ERG promotes T-acute lymphoblastic leukemiaand is transcriptionally regulated in leukemic cells by astem cell enhancer. Blood 117: 7079-7089.
47. Van der Meulen J, Speleman F, Van Vlierberghe P. 2014. TheH3K27me3 demethylase UTX in normal development anddisease. Epigenetics 9: 658-668.
48. Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F,Matthijssens F, Rondou P, Rosen M, Pieters T, Vandenberghe P, et al. 2015. The H3K27me3 demethylase UTX is a genderspecifictumor suppressor in T-cell acute lymphoblastic leukemia.Blood 125: 13-21.
49. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den Boer ML, Horstmann M, Kamps WA, et al. 2006. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acutelymphoblastic leukemia: a retrospective study of patientstreated according to DCOG or COALL protocols. Haematologica91: 1212-1221.
50. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G,Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, et al.2009. Somatic mutations of the histone H3K27 demethylasegene UTX in human cancer. Nat Genet 41: 521-523.
51. Van Vlierberghe P, Ferrando A. 2012. The molecular basis ofTcellacute lymphoblastic leukemia. J Clin Invest 122: 3398-3406.
52. Wang C, Lee JE, Cho YW, Xiao Y, Jin Q, Liu C, Ge K. 2012. UTXregulates mesoderm differentiation of embryonic stem cellsindependent of H3K27 demethylase activity. Proc Natl AcadSci 109: 15324-15329.
53. Welstead GG, Creyghton MP, Bilodeau S, Cheng AW, Markoulaki S, Young RA, Jaenisch R. 2012. X-linked H3K27me3demethylase Utx is required for embryonic development ina sex-specific manner. Proc Natl Acad Sci 109: 13004-13009.
54. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011. RNAiscreen identifies Brd4 as a therapeutic target in acute myeloidleukaemia. Nature 478: 524-528.